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Biofabrication is gaining interest as a mean to produce nanostructured functional 
materials because of its operational versatility and full scalability. Materials based on 
proteins are especially appealing as protein structure and functionality are adaptable by
genetic engineering. Furthermore, strategies and tools for protein production have 
been steadily developed and refined for more than 30 years. However, protein 
conformation and therefore activity might be sensitive to production conditions. We 
have explored here whether the downstream strategy influences structure and 
biological activities, in vitro and in vivo, of a self-assembling, CD44-targeted protein-
only nanoparticle produced in Escherichia coli. This has been done by the comparative 
analysis of particles built of soluble protein species or protein versions obtained by in 
vitro protein extraction from inclusion bodies, through mild, non-denaturing procedures.
These methods have been recently developed as a convenient alternative to the use of
toxic chaotropic agents for protein resolubilization from protein aggregates. The results 
indicate substantial differences in the physicochemical properties as well as in the 
biological performance at the systems level of the resulting material, whose building 
blocks show to be sensitive to the particular protein source. 




Protein materials are gaining interest in diverse arms of nanomedicine, especially in 
tissue engineering and drug delivery. This is because of the functional and structural 
versatility and tunability of proteins, the possibility to generate new functions through 
designing non-natural amino acid sequences, the unique merging between structure 
and function and the establishment of engineering principles to control protein self-
assembling at the nanoscale 1,2. Ribbons, tapes, fibres, hydrogels, films and particles 
result from the organized cross-interaction between discrete building blocks 3. These 
fall into two main categories, namely peptides and multidomain proteins. While short 
peptides are synthesized chemically, full-length proteins and many long peptides need 
to be produced by biological fabrication in recombinant cells. Since the methodological 
principles supporting recombinant protein production were already established in the 
late 70’s, we have accumulated experience, tools and know-how for almost 4 decades 
about the functioning and physiology of cell factories, especially Escherichia coli. The 
first insulin version approved for use was produced in E. coli, and an important fraction 
of the protein drugs currently in the market are also produced in this bacterial species 4.
Being the physiology of protein production more complex than formerly believed, 
genetics, genomics, proteomics, systems biotechnology and metabolic engineering are
increasingly providing progresses and optimization of bacterial protein production, 
aimed to improve yield and functional quality of target products 5,6. While some 
recombinant polypeptides are straightforward obtained as soluble versions, many other
protein species, in particular when having a non-bacterial origin or upon extensive 
engineering, result in insoluble aggregates named inclusion bodies (IBs) 7. Although in 
the last decade the biological properties of IBs have been deeply dissected at 
molecular and physiological levels8, their formation is, in most cases, unavoidable 9. 
For use as soluble species, for instance as drugs, target proteins that are produced as 
IBs need to be denatured and refolded in vitro by the application and progressive 
removal of solubilizing agents such as urea or guanidinium10,11. Being this approach 
convenient regarding some aspects (as these aggregates are a cost-effective and 
relatively pure source of protein), protein refolding from IBs involves complex protocols 
that need tedious development, the use of toxic chaotropic agents and a case-per-case
adaptation. 
More recently, and based on the realization that bacterial IBs contain significant 
fractions of properly folded protein species 12, non-denaturing protocols for direct 
protein extraction have been developed 13. They are based on mild treatment with 
detergents or organic solvents that promote the release of soluble or quasi-soluble 
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protein. Such releasable protein fraction is probably attached to core amyloid fibres that
form the IB skeleton by specific stereospecific interactions 14,15. Being highly promising 
in the case of polypeptides intended for conventional uses (for instance enzymes or 
hormones), these methods have been never tested in the fabrication of more complex 
protein structures such as smart protein nanoparticles, resulting from protein self-
assembling and intended, for instance, as vehicles for targeted drug delivery upon 
systemic administration. We have here explored the non-denaturing extraction of two 
tumor-homing protein nanoparticles (A5G27-GFP-H6 and FNI/II/V-GFP-H6) in which 
CD44-targeted peptides are displayed on GFP-based, self-assembling building blocks
16.  As these subunits are partially produced as soluble species and also as IBs, it has 
been possible to comparatively explore nanoparticle architecture, cell internalization 
and in vivo whole-body biodistribution when the oligomers resulted from either IB-
extracted or soluble building blocks. Our data demonstrate that the choice of the 
downstream procedure is not irrelevant regarding the final performance of the materials
but that instead compromises their functional quality and biological effectiveness at 
both cell and systems levels. 
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Material and methods
Protein design and biological production
The chimeric proteins A5G27-GFP-H6 and FNI/II/V-GFP-H6 contain the CD44-binding 
peptides A5G27 (fragment 2975-2987 from laminin α5 chain protein, RLVSYNGIIFFLK)
and FNI/II/V (fragment 1923-1991 from fibronectin protein, 
WQPPRARITGYIIKYEKPGSPPREVVPRPRPGVTEATITGLEPGTEYTIYVIALKNN 
QKSEPLIGRKKT) respectively, displayed at the amino terminus of a His-tagged 
enhanced GFP (Figure 1A). These proteins act as building blocks of self-assembling 
protein nanoparticles, intended as carriers for targeted drug delivery, that are 
internalized by CD44+ cells by receptor specific interactions and subsequent receptor-
mediated endocytosis16. While the cationic nature of the N-terminal peptides (milder for 
A527) promotes protein self-assembling, in combination with the H6 tail, they also act 
as CD44 ligands with distinguishable efficiencies 16.  The encoding genes were 
harboured in the plasmid pET22b, that was transformed into Escherichia coli BL21 (F–
omp ThsdSB(rB– mB–) gal dcmDE3, Novagen). Protein production was induced by the 
addition of 1 mM IPTG in bacterial cultures growing in LB medium plus ampicillin (100 
µg/mL) at 16°C and under stirring at 250 rpm. Upon overnight culture, bacterial cells 
were centrifuged for 15 min (5,000 g at 4°C) for harvesting.The medium-scale 
production of recombinant proteins was partially performed by the ICTS “NANBIOSIS”, 
more specifically by the Protein Production Platform of CIBER in Bioengineering, 
Biomaterials & Nanomedicne (CIBER-BBN)/ IBB, at the UAB (SepBioEs, 
http://http://www.nanbiosis.es/unit/u1-protein-production-platform-ppp/).Under these 
production conditions, soluble and aggregated protein species were observed in both 
cases.
Protein purification and preliminary characterization
Pellets of bacterial cells were resuspended in Tris buffer (20 mM Tris, pH 8.0, 500 mM 
NaCl, 10 mM imidazole) in the presence of protease inhibitors (Complete EDTA-Free, 
Roche, Basel, Switzerland). Cells were disrupted at 1,200 psi in a French press 
(Thermo FA-078A) and the lysate was centrifuged at 15,000 g for 45 min. The insoluble
fraction was kept apart for the purification of IBs and further protein extraction. The 
soluble fraction (named SN1) was filtered through 0.22 µm filter to be later submitted to
His-tag affinity chromatography in HiTrap Chelating HP 1 mL columns (GE Healthcare, 
Piscataway, NJ, USA) with an ÄKTA purifier FPLC System (GE Healthcare). Elution 
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was achieved by a linear gradient of 20 mMTris, pH 8.0, 500 mM NaCl, and 500 mM 
imidazole.
For protein extraction from IBs a previously published protocol 17 was slightly adapted. 
In summary, the insoluble cell fraction obtained from lysate centrifugation was 
resuspended twice with MilliQ H2O and centrifuged at 15.000 g for 30 min at 4 ºC; 
supernatants were named SN2 and SN3 respectively. The pellet was resuspended in 
Tris buffer (40 mM Tris HCl with 0.2 % N-lauroyl sarcosine, pH 8.0) with a ratio of 40 
mL buffer/g pellet in the presence of protease inhibitor (Complete EDTA-Free, Roche, 
Basel, Switzerland) and agitated for 24 h at room temperature. Sample was centrifuged
at 15,000 g for 45 min at 4 ºC and supernatant with resolubilized protein was filtrated 
before being purified by His-tag affinity chromatography using HiTrap Chelating HP 1 
mL columns (GE Healthcare) with an ÄKTA purifier FPLC System (GE Healthcare). 
Elution was achieved by a linear gradient of 20 mMTris HCl, pH 8.0, 500 mM NaCl, 500
mM imidazole and 0.1 % N-lauroyl sarcosine. For purification of FNI/II/V-GFP-H6, Tris-
HCl buffer was substituted for 166 mM NaHCO3 to avoid protein precipitation. Proteins 
were finally dialyzed overnight at 4 ºC against working buffer (166 mM NaHCO3 at pH 
7.4). For consistence, only proteins released from the ÄKTA purifier in the last major 
peak (those showing higher affinity for the matrix), were selected for further analyses in
all cases (for both soluble and IB-extracted protein versions).
Eluted protein-containing fractions were analyzed by both SDS 
electrophoresis/Coomassie Brilliant Blue staining and Western blotting using an anti-
His monoclonal antibody (Santa Cruz Biotechnology Inc., Heidelberg, Germany). 
Protein concentration was determined by Bradford’s assay as described elsewhere18.
Field Emission Scanning Electron Microscopy (FESEM) and Dynamic Light 
Scattering (DLS)
As a qualitative approach, purified proteins were diluted to 200 μg/mL working buffer, 
and 10 µL of each one were deposited onto silicon wafers (Ted Pella Inc., Redding, CA,
USA) for 2 min, the excess of liquid was adsorbed with Whatman paper and air dried. 
Ultrastructural morphometry samples (size and shape) was then observed at a nearly 
native state without coating with a high resolution in-lens secondary electron detector 
through a field emission scanning electron microscope Zeiss Merlin (Oberkochen, 
Germany) operating at 0.8 kV. As a quantitative approach, volume size distribution of 
nanoparticles was determined by DLS at 633 nm (in a Zetasizer Nano ZS, Malvern 
Instruments Limited, Malvern, UK) at a protein concentration of 1 mg/mL. DLS 
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measurements to assess protein stability in physiologic medium were performed after 2
h incubation of A5G27-GFP-H6 nanoparticles at 1.5 µM (45 µg/mL) in OptiPro® 
medium. Zeta-potential of these materials were determined in the same device once 
diluted in working buffer at 0.6 mg/mL final protein concentration.
Size Exclusion Chromatography (SEC)
The molecular weight and Stroke’s diameter distribution of protein nanoparticles were 
determined by SEC after injection of 100 μL-samples with working buffer at 0.5 mL/min,
in a previously calibrated Superdex 200 10/300 GL (Tricorn) column (GE Healthcare).
Fluorescence Spectroscopy
Different fluorescence emissions were measured at 25 ºC in a Variant Cary Eclipse 
Fluorescence Spectrophotometer (Agilent Technologies), using a 1-cm pathlenght 
quartz cuvette. Green fluorescence emission was determined for 1-mg/ml protein 
samples in working buffer at a detection wavelength of 510 nm and an excitation 
wavelength of 450 nm. The variation in the tertiary structure of A5G27-GFP-H6 
(containing a unique tryptophan residue) was analysed by intrinsic Trp-fluorescence for
0.5 mg/ml protein samples. Temperature-dependent Trp emission fluorescence was 
recorded at 330 nm every 0.5 ºC from 20 to 100 ºC using an excitation wavelength of 
280 nm. Scans were recorded along the 290-400 nm range at given temperatures after
8 min of temperature equilibration, and 10 scans were averaged.
Circular Dichroism
Far-UV circular dichroism (CD) was measured at 25ºC in a Jasco J-715 
spectropolarimeter to assess secondary structure differences. Proteins were analysed 
at 10 µM (0.3 µg/mL) in working buffer with 1 mm pathlength quartz cuvette. CD 
spectra were obtained over the wavelength range of 200-250 nm at a scan rate of 50 
nm/min, a response of 2 s, and a bandwidth of 1 nm. Ten scans were accumulated. To 
assess conformational differences, spectra were superimposed by applying a 1.5 
multiplication factor.
Protein modelling
The A5G27-GFP-H6 monomer was modelled by homology using Modeler 9v13 19 and 
the following templates: mouse laminin alpha2 chain lg4-5 domain pair (pdb entry 1okq,
residues A2789 to A2802, 21.4 % identity, 71.4 % similarity) 20 and  mouse laminin 
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alpha1 chain, domains lg4-5 (pdb entry 2jd4, residues A2905 to A2918, 28.6 % identity,
50 % similarity) 21 for A5G27 residues 1 to 14; residues 43 to 49 of the globular domain 
of Gallus gallus histone H5 (pdb entry 1hst 22 for residues 15 to 21 in the connecting 
segment (85 % identity); and pdb entry 1qyo for GFP 23 (residues 21 to 256, 98 % 
identity). The histidine tail was modelled by Modeller’s automodel function (residues 
257 to 263), with 500 models generated and sorted by their DOPE score 24. The 20 
models with best DOPE score were analyzed with the Electrostatic-Desolvation-Profile 
method 25, in order to predict putative protein-protein binding patches.
Total carbohydrate and lipid analysis
A phenol-sulphuric acid assay was performed to determine the total amount of 
carbohydrates present in protein samples. For that, 225 µg of protein were lyophilized 
and 150 µL of 18 M sulphuric acid were added and immediately, 30 µL of 5 % phenol. 
Samples were incubated at 90 ºC for 5 min, cooled to room temperature and optical 
density was measured at 490 nm. A glucose standard was prepared with a range from 
0 to 400 ng.
The total amount of lipids in the samples was analyzed by the sulfo-phospho vanillin 
colorimetric method. In short, 1 mg of each sample was lyophilized and dissolved in 
200 µL chloroform. After chloroform was evaporated, 100 μL of water were added. 
Samples were transferred to glass tubes and 2 mL of 18 M sulphuric acid were added. 
Then, samples were incubated for 10 min in a boiling water bath and subsequently 
cooled down in water bath at RT. After treatment with 5 mL phosphoric acid-vanillin 
reagent (85 % (v/v) phosphoric acid and 1.2 g/L vanillin (Sigma Aldrich, Steinheim, 
Germany)), the samples were warmed at 37 ºC for 15 min and cooled for 10 min in 
water bath at RT. Absorbance at 530 nm was measured. For the standard curve, a 
range of 10–100 μg triolein was used.
Cell line and cell manipulation
Human breast cancer cell line MDA-MB-231 was obtained from the ATCC (Rockville, 
MD, USA). MDA-MB-231 used for flow-cytometry and confocal imaging were 
maintained in RPMI 1640 medium supplemented with 10 % FBS and 6 mM GlutaMAX 
(Invitrogen, Carlsbad, CA, USA). MDA-MB-231 cells used for orthotopic mouse models
were cultured in DMEM-F12 medium supplemented with 10 % heat-inactivated fetal 
bovine serum (Lonza, Verviers, Belgium), L-glutamine and antibiotic-antimycotic 
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(Invitrogen) at 37 ºC in a humidified atmosphere containing 5 % CO2 and transfected 
as follows. 
Flow cytometry 
Cells were cultured on 24-well plates at 8·104 cells/well until reaching 70 % confluence. 
Media was removed and cells washed twice with PBS (Sigma-Aldrich, Steinheim, 
Germany). Then, cells were incubated with OptiPRO™ serum-free medium 
supplemented with L-glutamine with recombinant proteins dissolved at the convenient 
concentrations. Cells were incubated at 37 ºC and 5 % CO2 in a humidified atmosphere
for 24 h, and for 16 h, 6 h, 4 h, 2 h, 1 h and 30 min in the kinetics assay. Cells were 
then treated with 1 mg/mL trypsin for 15 min to detach cells and remove any attached 
protein from cell membrane 26. This was followed by the addition of complete medium 
and centrifugation at 1,400 g for 5 min. Collected cells were resuspended in DPBS. 
Protein internalization was analyzed using a FACS-Canto system (Becton Dickinson, 
Franklin Lakes, NJ, USA), using a 15 W air-cooled argon-ion laser at 488 nm 
excitation. GFP fluorescence emission was measured with detector D (530/30 nm band
pass filter). Results were usually normalised with the specific fluorescence for each 
protein (by fluorescence signal/(fluorescence signal/(mg·ml-1) protein)). Although 
settings of flow cytometry and conventional fluorimeter are different and fluorescence 
units are not equivalent, the normalization results in data that are representative of 
protein amounts. Experiments were performed in duplicate.
Confocal analysis
Cells were seeded on Mat-Teck culture plate (Mat Teck Corp., Ashland, MA, USA) with 
RPMI 1640 medium at 200,000 cells/plate for 24 h. Media were removed and replaced 
by OptiPRO™ serum-free medium supplemented with L-glutamine and containing the 
recombinant proteins at 1.5 µM (44 µg/mL).After incubation for 4 h, cells were washed 
with PBS. Plasma membranes were then labelled with 2.5 μg/ml CellMaskTM Deep Red 
(Molecular Probes, Eugene, OR, USA) and cell nuclei with 0.2 μg/mL Hoechst 33342 
(Molecular Probes) for 5 min in darkness. Then, cells were washed with PBS and 
complete medium was added. Stained cells were examined using TCS-SP5 confocal 
laser scanning microscope (Leica Microsystems, Heidelberg, Germany) with a Plan 
Apo 63×/1.4 (oil HC × PL APO l blue) objective. Hoechst 33342 was excited with a blue
diode (405 nm) and detected at the 415-460 nm range. GFP was excited with an Ar 
laser (488 nm) and detected at the 525-545 nm range. CellMask was excited with a 
HeNe laser (633 nm) and detected at the 650-775 nm range. Confocal images were 
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deconvolved using Huygens Essential deconvolution software version 4.4.0p6 (SVI, 
Leiden, The Netherlands). The confocal channels representing specific emission 
spectra were separated and deconvolved using the classical maximum likelihood 
estimation with the following parameters changed: quality change threshold = 0.01%, 
maximum iteration = 50, and signal-to-noise per channel values = 20, 14, and 15, 
respectively. The data sets were then imported into Imaris 3D visualization software, 
version 6.1.0 (Bitplane, Zürich, Switzerland) and the isosurface projections were 
calculated with the Surpass tool. 
Analysis of protein stability
Protein stability was analyzed in triplicate at 115 µg/ml final concentration in 
reconstituted human plasma (Sigma-Aldrich, Ref: S225-5 ml), after 30 min, 1 h, 2 h, 4 h
and 24 h of incubation at 37 ºC, under mild agitation. Protein green fluorescence was 
determined as described above. Sample at 24 h was centrifuged and fluorescence of 
the soluble fractions was re-analyzed to discard protein aggregation.
Orthotopic mammary fat pad mouse models 
Female athymic nude mice (Harlan Interfauna Iberica, Barcelona, Spain) were kept in
pathogen-free conditions and used at 6 weeks of age. Animal care was handled in
accordance with the Guide for the Care and Use of Laboratory Animals of the Vall
d'Hebron University  Hospital  Animal  Facility  and the experimental  procedures  were
approved by the Animal Experimentation Ethical Committee at the institution. All in vivo
experiments  were  performed  by  the  ICTS  “NANBIOSIS”,  more  specifically  by  the
CIBER-BBN’s In Vivo Experimental Platform of the Functional Validation & Preclinical
Research  (FVPR)  area  (http://www.nanbiosis.es/unit/u20-in-vivo-experimental-
platform/). 
MDA-MB-231 cells (2.5×106) suspended in 200 μL of phosphate buffered saline (PBS)
with Matrigel (1:1) (BD Bioscience, Bedford, MA, USA) were implanted into the right
abdominal mammary fat pad (i.m.f.p.). Tumor growth was monitored twice a week by
conventional caliper measurements (D×d2/2, where D is the major diameter and d the
minor diameter). Once the tumors reached a median volume of 200 mm3, mice were
randomized in the different treatment groups (n=3-4) according to their tumor volume,
and a biodistribution study was performed.
In vivo whole-body biodistribution
10
MDA-MB-231 i.m.f.p. tumor-bearing mice were treated intravenously with a single dose
of 40 mg/kg of A5G27-GFP-H6rIB and A5G27-GFP-H6 sol in 166 mM NaHCO3 pH 7.4 
buffer. Then, mice were euthanized at 10 min, 30 min, 60 min and 5 h post 
administration. Blood was collected from each animal by cardiac puncture and 
processed for plasma fractionation. Tumors and the major organs such as liver, kidneys
and lungs were dissected from mice, weighted and imaged by ex vivo fluorescence 
imaging (FLI). Plasma and tissues samples were harvested and stored at −80 °C.
Ex vivo FLI was performed using an IVIS Spectrum Imaging System (PerkinElmer Life 
Science, Boston, MA, USA), and images and measurements were acquired and 
analyzed using the Living Image 4.3 software (PerkinElmer). The light emitted from the 
fluorescent A5G27-GFP-H6 rIB and A5G27-GFP-H6 sol was detected, digitalized and 
electronically displayed as a pseudocolor overlay onto a gray scale animal image. 
Regions of interest (ROI) from displayed images were drawn manually around the 
fluorescent signals and quantified as Radiant Efficiency. The mean fluorescence 
intensities and corresponding standard errors of the mean (SEM) were determined for 
each experiment. All the analyses and graphs were performed using Prism 5 software 
(GraphPad, San Diego, CA, USA).
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RESULTS
Protein production. A5G27-GFP-H6 and FNI/II/V-GFP-H6 were produced in E. coli as
soluble species, but at higher proportions, as insoluble material as well (Figure 1 B) in 
form of fluorescent IBs (Figure 1 C). Soluble A5G27-GFP-H6 showed a molecular 
weight of about 30 kDa compatible with that expected for the full-length protein, while 
the aggregated protein also appeared in multimeric forms, as described for GFP and 
some GFP-derived proteins 27. Soluble FNI/II/V-GFP-H6 partially occurred as a 
degradation band, that was fully absent in the insoluble protein fraction (Figure 1 B). 
Soluble and insoluble (IB) protein fractions were separated and processed as depicted 
in Figure 2 A. Soluble protein was extracted from IBs by adapted mild procedures, 
recently developed 13 to avoid the conventional, complex and product-specific 
denaturation-based refolding protocols that rely on the multi-step use of chaotropic 
agents10,11. Upon French press cell-disruption, extraction of GFP from GFP IBs 
maintains the native specific fluorescence 28, thus stressing the mildness of the 
procedure. This novel category of separation methods is based on the recognition of 
functional proteins occurring in bacterial IBs29,30, that are architectonically combined 
with amyloidal networks 31-34. Because of the releasable properties of the soluble 
protein fraction, IBs show great promise as cost-effective functional materials and 
drugs35. Straightforward soluble protein (sol) and IB-released protein (rIB) versions 
were both purified by His-tag affinity chromatography. While A5G27-GFP-H6 was 
always observed as a single band with an electrophoretic mobility compatible with that 
of the full length protein, soluble FNI/II/V-GFP-H6 appeared as two distinguishable 
species eluted in different fractions (Figure 2 B), that were identified by MALDI-TOF as 
the full length proteins and as a stable degradation fragment (FNI/II/V-GFP-H6 deg) of 
about 30 KDa (Figure 2 C), compatible with a GFP-H6-like form lacking most part of 
the amino terminal homing peptide (in contrast to the intact carboxy terminus as 
indicated by His-based successful purification). By fine MALDI-TOF analysis, some 
degradation fragments were also observed in the samples of soluble A5G27-GFP-H6. 
In both proteins, rIB versions uniquely contained full-length forms (Figure 2 C), which 
stresses a potential advantage of IB protein extraction as a choice downstream 
procedure. 
Architectonic characterization of nanoparticles. The material resulting from 
alternative downstream methods was analysed regarding their ability to form 
nanoparticles, a feature that is not displayed by the parental GFP-H6 construct 36. 
Interestingly, DLS determination revealed architectonic differences in the resulting 
materials depending on the taken approach (Figure 3 A). For both proteins, rIB forms 
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resulted in larger nanoparticles than when derived from soluble protein versions (29 nm
versus 14 nm in the case of A5G27-GFP-H6, and 29 nm versus 18 nm in the case of 
FNI/II/V-GFP-H6). The formation of nanoparticles necessarily involves the N-terminal 
tail, as a control GFP-H6 is unable to form them and remain as unassembled material
36. Monomers are not observed in the DLS screening of both A5G27-GFP-H6 and 
FNI/II/V-GFP-H6, indicating that the self-assembling is a very efficient event. 
Interestingly, FNI/II/V-GFP-H6 deg tended to aggregate as highly polydisperse 
materials (not shown). The two versions of A5G27-GFP-H6 nanoparticles, showing the 
highest internal variation between size of sol and rIB forms, were further explored to 
fully assess the architectonic differences suggested by DLS. Indeed, both FESEM 
imaging of the samples (Figure 3 B) and SEC (Figure 3 C) fully confirmed the larger 
size of rIB version of A5G27-GFP-H6 nanoparticles, besides the SEC provided data 
fully matching with that from DLS. Minor size variation in the analyses of A5G27-GFP-
H6 sol when comparing DLS and SEC might be due to different ways to compute data 
and to the average nature of DLS measurement. Despite these differences, exposure 
of electrostatic charges was similar when comparing A5G27-GFP-H6 sol and A5G27-
GFP-H6 rIB (Figure 3 D), suggesting only moderate changes in the spatial disposition 
of the building blocks and also the absence of charged contaminants remaining from 
the purification process. Despite the low values of Z potential, aggregation was not 
observed at exception of FNI/II/V-GFP-H6 deg. To explore potential variability in the 
protein conformation when assembled in alternative particle versions, we analysed the 
specific fluorescence of the assembled proteins  compared with the parental 
monomeric GFP-H6. All protein versions were fluorescent (Figure 3 E), what ensured 
convenient tracking in further in vitro and in vivo experiments. The specific 
fluorescence of FNI/II/V-GFP-H6 deg was indistinguishable from that of the parental 
GFP, while the rest of proteins were less fluorescent. This observation indicated that 
the fusion of the ligands to the amino terminus of GFP resulted in an altered 
conformation of the chromophore or in an enhanced quenching, and that the truncated 
version of FNI/II/V-GFP-H6, that was successfully purified by His-tag affinity, was 
lacking part or the complete N-terminal ligand. Interestingly, the major decrease in the 
specific fluorescence was observed in both rIB versions (3-fold compared with parental 
GFP), suggesting that the expanded size in the resulting nanoparticles could be linked 
to a particular protein conformation or conformational set that promote a reduced 
fluorescence emission, specifically favoured upon protein extraction from IBs.
In vitro cell internalization of protein nanoparticles. To evaluate how these 
nanoparticle versions perform in contact with target cells and in particular, to explore 
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potential differences among them, we exposed CD44+ cells to the same amount of 
proteins for comparative purposes. Samples were analysed by flow cytometry after a 
harsh trypsin treatment specifically developed to remove externally associated 
protein26. As expected, the truncated FNI/II/V-GFP-H6 deg only showed background 
cell penetration levels, much lower than those observed for the assembled 
nanoparticles (Figure 4 A). In particular, A5G27-GFP-H6 rIB showed significantly higher
cell penetrability than the rest of nanoparticles, what was compatible with confocal 
microscopy taking into account the lessened fluorescence emission of this nanoparticle
version (Figure 4 B). The enhanced association of A5G27-GFP-H6 rIB with target cells 
was fully confirmed by further kinetic internalization analyses (Figure 5 A, B), that 
occurred in absence of cell toxicity (Figure 5 C). The unassembled GFP-H6, in 
contrast, remains extracellularly when cell cultures are exposed to this  material 36.
In an attempt to investigate if the difference in size and cell interactivity between 
A5G27-GFP-H6 sol and A5G27-GFP-H6 rIB could be due to different composition in 
the nanoparticles (that is, traces of contaminants from the cell factory), we determined 
the lipid (18.5 µg/mg ± 0.7 versus 19.9 µg/mg ± 0.5) and carbohydrate (0.10 µg/mg ± 
0.01 versus 0.11 µg/mg ± 0.03) content in both, showing no significant differences 
(p>0.24) (Figure 6 A). Also, the addition of sarkosyl (a potential contaminant of A5G27-
GFP-H6 rIB) to A5G27-GFP-H6 sol just before incubation with cells, does not increase 
cell interactivity or penetrability of the construct (despite a slight, non-significant 
enhancement), remaining the fraction of cell-associated protein a 26 % of A5G27-GFP-
H6 rIB (Figure 6 B). The homogeneity in the electrostatic charge among the variant 
materials measured by Zeta-potential analysis (Figure 3 D) also allows discarding the 
significant occurrence of anionic detergents used in the IB protein extraction. 
Therefore, we concluded that as suggested by morphological data (Figure 3 A, B) and 
fluorescence recording (Figure 3 E), the discrimination of biological behaviour between 
A5G27-GFP-H6 sol and A5G27-GFP-H6 rIB might be derived from conformational 
variability in the nanoparticles as derived from distinct separation methods downstream
the biological fabrication. Importantly, the mild extraction of monomeric GFP from IBs 
using the same protocol than in the present study does not affect specific fluorescence
28.  Therefore, the differences in the specific fluorescence observed here between the 
two A5G27-GFP-H6 particle versions must be linked to the ability shown by this protein
to oligomerize as nanoparticles (in which monomers probably encounter 
distinguishable molecular environments).  
The hypothesis of conformational variability between A5G27-GFP-H6 sol and rIB 
nanoparticles was supported by secondary and tertiary structure analyses (Figure 7). 
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The far-UV CD spectra revealed changes in ellipticity at around 210 nm, revealing that 
β-sheet content is somewhat higher in rIB oligomers than in those obtained from the sol
version (Figure 7A). In addition, the rIB spectrum had to be multiplied by a 1.5 factor in 
order to be superimposed to the sol spectrum, which reflects that rIB nanoparticles are 
less soluble than sol nanoparticles, and, in turn, concurs with a β-sheet-rich associating
conformation. Differences on tertiary structure were determined by measuring 
tryptophan intrinsic fluorescence at different temperatures. Temperature-dependent 
fluorescence intensity at 330 nm presents different decreasing slope for each 
nanoparticle, with that for rIB showing a particular transition between 70 and 80 ºC 
(Figure 7B).In order to delve into this heat-induced different behaviour, Trp emission 
spectra were recorded at different temperatures (Figure 7C-D). Although intensity 
decreases with temperature in both cases (as already shown in Figure 7B), it is 
noteworthy that the maximum of the sol variant spectrum suffers a slight redshift (from 
331 nm to 335 nm) upon increasing temperature, whereas the rIB variant behaves the 
opposite, blueshifting from 329 nm to 310 nm; in addition, the maximum of the spectra 
remains the same from 20 to 60 ºC and suddenly blueshifts between 60-80º C, in 
consonance with the mentioned particular transition in the denaturation plot followed by
intensity at 330 nm (Figure 7B). Therefore, it can be concluded that whereas the sol 
variant partially unfolds or initiates an unfolding process (albeit not reaching the fully 
unfolded state, characterized by a maximum at 355 nm), the rIB variant packs such 
that Trp residues are buried within the nanoparticle. Moreover, the maxima of the rIB 
initial spectra (20ºC) is 2 nm blueshifted with respect to the one for the sol variant and 
this effect, although slight, is also observed at the temperature closest to physiologic 
conditions (at 40ºC the difference among both variants is 3 nm), suggesting that, in 
vivo, rIB nanoparticles may display a more compact conformation than those obtained 
from the soluble variant. 
In vivo biodistribution of nanoparticles. To investigate any potential variation in the 
whole-body biodistribution maps of A5G27-GFP-H6 derived nanoparticles, we 
administered these materials to CD44+ breast MDA-MB-231 intramammary tumor-
bearing mice, in which we have previously demonstrated selective targeting of the 
A5G27-GFP-H6 sol version16. Tumor targeting was similar when comparing A5G27-
GFP-H6 sol and A5G27-GFP-H6 rIB nanoparticles (Figure 8 A), proving that the 
structural differences between the particles did not affect the specificity in the 
interaction with the cell surface CD44 receptor in vivo. However, accumulation of the 
protein material in secondary, non-target organs was clearly unequal depending on the 
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material type. In particular, A5G27-GFP-H6 rIB nanoparticles showed much less 
retention in kidney than their A5G27-GFP-H6 sol counterparts, probably associated to 
lower extent of renal filtration derived from the higher size of this particle isoform and a 
weakened disassembly during circulation. Accordingly, the larger A5G27-GFP-H6 rIB 
nanoparticles followed an enhanced liver accumulation in contrast to A5G27-GFP-H6 
sol nanoparticle. The higher size of this particle isoform and probably an enhanced 
stability during circulation might account for such altered pattern. Even more, A5G27-
GFP-H6 rIB accumulated in lung at higher extents than its soluble counterpart, being 
most likely indicative of initial aggregation upon administration and their first-pass 
retention in lung capillaries (Figure 8 A). Interestingly, aggregation of this protein had 
never been observed in vitro in storage or working buffers (Figure 3 A), but it is well 
known that the presence of proteins and high salt content in complex media may affect 
the composition, interactivity and properties of protein nanoparticles 37. In this regard, 
when incubating A5G27-GFP-H6 rIB in a protein-containing medium such as OptiproTM,
protein clustering was indeed observed (Figure 8 B) through a shift of the DLS protein 
peak towards larger sizes and by the decrease of stability revealed by the higher 
polydispersion index. Such clustering might be indeed responsible for the slight 
accumulation observed in lung (Figure 8 A). When incubating A5G27-GFP-H6 rIB in 
human plasma followed by centrifugation, the GFP fluorescence signal was not 
reduced (Figure 8 C), indicating the soluble nature of any A5G27-GFP-H6 rIB cluster 
that might be formed in protein-containing media. The small values of Z potential 
(Figure 3 B) could contribute to the observed tendency to form supramolecular clusters 
in complex media, that still being soluble and functional, might be favoured by a higher 
particle size in the case of the IB version. 
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Discussion
The microbial synthesis of nanostructured materials is gaining interest versus the most 
conventional chemical production because of the flexibility, scalability and cost 
effectiveness of cell factories, and due to the inherent, environmentally friendly nature 
of biological fabrication 38-40. Different types of materials, including proteins3, metals 41 
and polymers 42,43 are produced in microbial cells, among which many of them are 
intended for biomedical applications44. The adaptation and implementation of 
microorganisms alternative to gram negative bacteria is expanding the diversity of 
products resulting from biological fabrication, especially concerning difficult-to-express 
proteins45-49. Being E. coli together with its expression vectors an extremely versatile 
toolbox in bioproduction, the recent development and application of endotoxin-free 
strains of this species 50,51 paves the road for a reassessment of this cell factory in 
BioPharma. Among nanoscale microbial products, those based on proteins exhibit 
particular properties associated to the unique integration of structure and function, 
properties that can be tailored and re-designed by plain genetic engineering. In this 
regard, the emergence of principles to rationally engineer protein self-assembling 52-58 
allows the production, in recombinant cells, of a spectrum of protein materials such as 
particles, fibres, films, ribbons and hydrogels 1. 
Despite the enormous potential in the biofabrication of protein nanostructures and the 
vast experience in recombinant protein production and purification, how 
production/separation methods might influence the performance of smart and 
structurally complex protein materials (like tumor-homing drug vehicles) is, 
unfortunately, a neglected but critical issue. We have here demonstrated that the 
downstream processing of recombinant CD44-targeted protein nanoparticles influences
material architecture (Figure 3), protein conformation within the nanoparticle (Figure 7),
cell penetrability in vitro (Figure 4) and whole-body biodistribution upon in vivo systemic
administration (Figure 8). Since many recombinant proteins used in pharmacology 
(including insulin) are recovered from bacterial IBs, the implementation of methods to 
recover soluble protein from those aggregates has been a critical issue in protein 
biotechnology. In contrast to conventional protocols based on the case per case 
exploration of denaturation and further optimal refolding conditions of IB proteins 10,11, 
the recently developed milder protocols for non-denaturing protein extraction are 
technically simpler 13. Also, aimed to release already soluble or quasi-soluble protein 
species occurring in IBs, they are essentially universal and can be applied transversally
irrespective of the IB protein species. 
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The protein nanoparticle explored here as model, namely A5G27-GFP-H6, is slightly 
larger when extracted from IBs than when purified as plain soluble species (Figure 3 A-
C). This version shows enhanced cell penetrability into CD44+ cells upon exposure 
(Figures 4, 5), although it appears to be slightly more sensitive to cell proteases than 
the soluble counterpart upon endosomal internalization, as inferred by the comparison 
of the respective uptake kinetics (Figure 5 B). Such differential performance is not 
influenced by potentially associated contaminants such as carbohydrates or lipids, as 
they have not been detected (Figure 6 A). Also, divergent properties appear as not 
linked to charged agents such as anionic detergents used in protein extraction, since 
the Z-potential of the material remains essentially unchanged irrespective of the 
purification procedure (Figure 3 D) and the addition of N-Lauroyl sarcosine to A5G27-
GFP-H6 sol nanoparticles does not upgrade cell uptake to the levels achieved by 
A5G27-GFP-H6 rIB (Figure 6 B). In addition, the fact that A5G27-GFP-H6 rIB 
nanoparticles do not contain higher amounts of lipids (Figure 6 D) also allows 
discarding the formation of nanodiscs, well known lipid-protein structures stabilized by 
detergents and commonly observed upon purification of membrane proteins 59,60. In this
regard, all these data indicate that the properties distinguishing A5G27-GFP-H6 sol and
A5G27-GFP-H6 rIB nanoparticles are intrinsic to the material and not determined by 
the used separation procedure. That A5G27-GFP-H6 sol and A5G27-GFP-H6 rIB 
materials are basically distinct can be inferred from their differential specific 
fluorescence (Figure 3E). Since it has been described that the fluorescence of an 
unassembled GFP is unchanged when produced in soluble form or when extracted 
from IBS by the same method used here 28, the assembling pattern of A5G27-GFP-H6 
must be different when produced as soluble version of as IBs. The arrangement of the 
whole material rather than the conformation of individual building blocks would be then 
responsible for the differential architecture and biological function, as further supported 
by the differential behaviour upon thermal denaturation found between these oligomer 
variants (Figure 7 B-D). The GFP beta-barrel domain contains a predicted protein-
protein interaction patch that overlaps with the GFP dimer interface, in a region that 
has several residues known to be involved in the modulation of the intensity of the 
fluorescence emission (Figure 9B) 61. It is thus very likely that relative differences in the 
arrangement of monomers in the two versions of A5G27-GFP-H6 of nanostructures 
(sizing 14 nm and 30 nm) might result in different molecular environments for the GFP 
chromophore and the modulator residues, leading to the observed differences in green 
fluorescence, CD and intrinsic Trp florescence upon thermal denaturation (Figure 7). 
The differential architecture of the materials according to their source (soluble or IB-
embedded), might be indicative of the nanoparticles, or at least some of their 
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precursors, being already assembled into IBs, what could be mechanistically allowed 
by the high porosity and hydration of these inclusions 62. A different molecular 
environment when compared with the cytosol would favour or force alternative 
arrangements of the building blocks (Figure 9A). 
In this line, the SEC analysis reveals a higher number of building blocks in A5G27-
GFP-H6 rIB nanoparticles when comparing with sol versions (Figure 3 C), and the 
enhanced cell penetrability might be due to a higher number of CD44-targeted peptides
exposed on the materials surface, without denying the external disposition of the 
ligands from sol version. Although displaying different size, the electrokinetical potential
(Figure 3 D) remains constantly negative for both types of nanoparticles, suggesting 
that surface charge is positive and that the monomers are faced with protruded 
orientation (Figure 9A). On the other hand, while size determination in cellular uptake 
of nanoparticles requires an important variability range to be effective 63-65, milder 
differences in multivalence regarding receptor binding (that is, number of reactive 
building blocks), might have a more visible role in the receptor-mediated penetrability of
protein nanoparticles 66. Of course, particular structural and functional features affecting
the display of the homing peptide might influence the whole nanoparticle performance, 
as some (enhanced size) but not all (enhanced cell penetrability) of the properties of 
A5G27-GFP-H6 rIB are replicated in the related FNI/II/V-GFP-H6 rIB construct (Figures
3, 4 and 5).
At the systems level, A5G27-GFP-H6 rIB and A5G27-GFP-H6 sol nanoparticles target 
the tumor tissue similarly, but their side accumulation in non-target organs is clearly 
different (Figure 8 A). Regarding renal filtration, the major route for excretion of small 
materials, larger A5G27-GFP-H6 rIB nanoparticles showed low retention in kidney 
compared to A5G27-GFP-H6 sol counterparts. Larger nanoparticles are able to escape
glomerular filtration and hold a longer plasma half-life, but are also prone for the uptake
by the organs of the reticuloendothelial system such as the liver and lung 67,68, as it 
happens here with the A5G27-GFP-H6 rIB version. In addition, the higher accumulation
of this construct in lung may be also due to initial clustering of nanoparticles and their 
first-pass retention in lung capillaries after systemic administration. The highest 
prevalence of A5G27-GFP-H6 rIB in the liver might be also enhanced by enlarged 
exposure of protein-protein interaction-prone regions 69,70 (Figure 9 B, C) that at the 
same time, might favour protein clustering as supramolecular structures and retention 
in lung. In agreement, DLS of A5G27-GFP-H6 rIB in protein-containing physiological 
media (Figure 8 B) indicates particle clustering, a fact not observed in storage buffer 
(Figure 3 A). However, these larger structures show a high polydispersion index (Figure
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8 B), indicative of instability, and they cannot be removed by centrifugation (Figure 8 
C), indicative of solubility. Decreased renal filtration is advantageous in in vivo 
administration of protein vehicles as circulation time is expanded and the targeting 
opportunities of any payload drug are consequently enhanced 71.
Results obtained in the present study indicate that cell-targeted protein nanoparticles 
exhibit differential performance depending on whether the materials derive from the E. 
coli soluble cell fraction or they are extracted from the soluble/quasi soluble protein 
fraction within IBs. In this context, the impact of the organization of the building blocks 
in oligomers on the whole performance of complex protein materials is an emerging 
matter of concern that should be investigated more deeply when designing protein-
containing biomaterials, especially for biomedical applications. Being probably 
irrelevant for most of conventional applications, protein self-assembling into functional 
materials with complex activities (such as cell-targeting) might be more sensitive to the 
conformational constraints imposed by the intracellular location upon biofabrication.
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Figure 1.Protein production. A) Schematic representation of the gene fusions used in 
this study consisting, from N- to C-terminal, of a CD44 ligand (either A5G27 or 
FNI/II/V), a linker (L) sequence (GGSSRSSS), the EGFP protein and a His(6) tag. 
Lengths of boxes are approximate and do not represent accurate sizes of the genes. 
Theoretical molecular masses of the encoded proteins are indicated in kDa. Additional 
information about these constructs can be found elsewhere16. B) Western Blot analysis 
of soluble (S) and insoluble (I) crude protein extracts obtained from protein-producing 
E. coli BL21. C) Fluorescence microscopy images of E. coli BL21 protein producing 
cells 16 h after addition of IPTG) (top). Merging of fluorescence and phase contrast 
images of the same fields to show the localization of fluorescent aggregates (green 
particles) within cells (black areas; bottom). 
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Figure 2. Protein purification strategy. A) Schematic representation of purification 
protocol for straightforward soluble protein (sol, light grey boxes) and for protein 
extracted from IBs (rIB, white boxes). Common steps are shown in dark grey boxes. B) 
Coomassie Brilliant Blue stained SDS-PAGE gel of purification fractions of A5G27-
GFP-H6 and FNI/II/V-GFP-H6 obtained from both type of materials (soluble protein 
fraction and rIB). Fractions containing the pure protein are those from 20-26, 8-12, 10-
14 and 17-20 for A5G27-GFP-H6 sol, A5G27-GFP-H6 rIB, FNI/II/V-GFP-H6 sol and 
FNI/II/V-GFP-H6  rIB respectively. Q: loaded supernatant, F: flowthrough, W: wash, 4-
26: eluted fractions. C) Protein integrity analysis by molecular weight determination 
through MALDI-TOF. (sol) indicates soluble protein and (rIB), protein extracted from 
IBs. (deg) refers to the soluble truncated version of FNI/II/V-GFP-H6.
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Figure 3.Qualitative and quantitative analyses for physicochemical and morphometric 
(size and shape) characterization of nanoparticles. A) DLS analysis of nanoparticle 
size. Peak sizes in each version are indicated above the corresponding plot. B) FESEM
images of A5G27-GFP-H6 nanoparticles showing higher magnification in the insets. 
Bars indicate 50 nm. C) SEC of A5G27-GFP-H6 nanoparticles. Peak sizes are 
indicated. D) Z-potential of A5G27-GFP-H6 nanoparticles, indicating the values of the 
peaks. E) Specific fluorescence of different nanoparticle versions referred to that of the 
parental GFP-H6 protein. *, p<0.001.
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Figure 4.  Cell  penetrability  of  nanoparticles  in  cultured cells.  A)  Amount  of  protein
internalized in MDA-MB-231 cells upon 24 h of exposure, estimated from intracellular
fluorescence and the specific  fluorescence of  each protein version.  A harsh trypsin
treatment was applied as described to eliminate externally attached protein material 26.
In the inset, confocal images of the amino truncated FNI/II/V-GFP-H6deg-exposed cells
showing only background signal.  Mean ± SEM are displayed.  B) Confocal images of
cultured MDA-MB-231 cells exposed to nanoparticles formed by full-length proteins.
Blue signals represent DNA and red signals cell membranes. In all cases bars indicate
10 µm.
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Figure 5. Kinetics of cell penetrability of nanoparticles in cultured cells. A) Flow 
cytometry analysis of MDA-MB-231 cells exposed to FNI/II/V-GFP-H6 derivatives, 
including the truncated version FNI/II/V-GFP-H6 deg. B) Flow cytometry analysis of 
MDA-MB-231 cells exposed to A5G27-GFP-H6 derivatives. C) Cell viability at different 
times of exposure to increasing concentrations of A5G27-GFP-H6 rIB. All data are 
displayed as mean ± SEM.
27
Figure 6. Compositional analyses of A5G27-GFP-H6 nanoparticles. A) Content of 
carbohydrates and lipids in purified nanoparticles. B) Effect of N-Lauroyl sarcosine, 
added just before incubation with cells, in the cell penetrability of A5G27-GFP-H6 sol 
nanoparticles. All data are displayed as mean ± SEM. *, p<0.001; **, p<0.002. 
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Figure 7. Conformational analyses of A5G27-GFP-H6 nanoparticle variants. A) 
Secondary structure analysis by far-UV CD spectroscopy at 25 ºC. Spectra were 
superimposed by applying a 1.5 multiplication factor. B) Temperature denaturation 
followed by Trp emission fluorescence at 330 nm. C) Tertiary structure analysis by Trp-
fluorescence spectroscopy at different temperatures. The maximum of each spectrum 
is indicated. Arrows represent the red and blue-shift of fluorescence maximum with 
temperature for A5G27-GFP-H6 sol and rIB versions respectively.
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Figure 8. Biodistribution and stability in physiological medium of A5G27-GFP-H6 
nanoparticles. A) Tumor- and tissue-accumulation map of A5G27-GFP-H6 
nanoparticles by ex vivo determination of fluorescence in selected organs, excised 30 
min after systemic administration of the materials. Mean ± SEM are displayed. B) 
Structural stability of A5G27-GFP-H6 nanoparticles after 2 h incubation in OptiProTM 
medium as measured by DLS. In blue line, OptiProTM control sample. Polydispersion 
indexes (PdI) of protein materials are indicated in the plots.. C) Stability of A5G27-GFP-
H6 nanoparticles when incubated with human plasma over 24 h, measured by 
fluorescence emission at 510 nm. Potential sedimentation of insoluble protein materials
was explored by determining the reduction of fluorescence of the soluble fraction after 
centrifugation (in the 24 h soluble sample).
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Figure 9. Putative organization patterns of A5G27-GFP-H6 nanoparticles as defined by
alternative exposure of hydrophobic patches. A) Different dispositions of building 
blocks, depending on the protein source or downstream treatment might promote 
differential arrangements in the oligomers. A different pattern of protein-protein cross-
interactions might influence not only particle geometry and size, but also relevant 
physicochemical and biological properties such as solubility, aggregation and liver 
uptake. B) Probability (from white to intense red) of A5G27-GFP-H6 residues belonging
to a protein-protein interaction patch, as derived from prediction frequencies for the 
twenty best-scoring models of the protein construct. Residues 148, 164, 202, 203 72, 
which are known to be involved in the modulation of the intensity of fluorescence 
emission 73, are shown as balls & sticks and are clearly found in the predicted 
interaction patch. C) The dynamic dimensions of the cylindrical are between 3.7 nm to 
6.1 nm (radius) and between 4.9 nm to 8.8 nm (height). The lower bounds correspond 
to the values measured for the GFP beta-barrel and the upper bounds correspond to 
the largest values measured for the 20 best models (including the tails) generated.
Reference List
1 Ferrer-Miralles,N. et al. (2015) Engineering protein self-assembling in protein-based 
nanomedicines for drug delivery and gene therapy. Crit Rev. Biotechnol. 35, 209-221
2 Seras-Franzoso,J. et al. (2015) Integrating mechanical and biological control of cell 
proliferation through bioinspired multieffector materials. Nanomedicine. (Lond) 10, 873-
891
31
3 Corchero,J.L. et al. (2014) Recombinant protein materials for bioengineering and 
nanomedicine. Nanomedicine. (Lond) 9, 2817-2828
4 Ferrer-Miralles,N. et al. (2009) Microbial factories for recombinant pharmaceuticals. 
Microb. Cell Fact. 8, 17
5 Mahalik,S. et al. (2014) Genome engineering for improved recombinant protein 
expression in Escherichia coli. Microb. Cell Fact. 13, 177
6 Lee,S.Y. et al. (2012) Systems metabolic engineering, industrial biotechnology and 
microbial cell factories. Microb. Cell Fact. 11, 156
7 Villaverde,A. and Carrio,M.M. (2003) Protein aggregation in recombinant bacteria: 
biological role of inclusion bodies. Biotechnol. Lett. 25, 1385-1395
8 Villaverde,A. et al. (2015) Functional protein aggregates: just the tip of the iceberg. 
Nanomedicine. (Lond) 10, 2881-2891
9 Baneyx,F. and Mujacic,M. (2004) Recombinant protein folding and misfolding in 
Escherichia coli. Nat. Biotechnol 22, 1399-1408
10 Vallejo,L.F. and Rinas,U. (2004) Strategies for the recovery of active proteins 
through refolding of bacterial inclusion body proteins. Microb. Cell Fact. 3, 11
11 Singh,S.M. and Panda,A.K. (2005) Solubilization and refolding of bacterial inclusion 
body proteins. J. Biosci. Bioeng. 99, 303-310
12 Gonzalez-Montalban,N. et al. (2007) Recombinant protein solubility-does more 
mean better? Nat. Biotechnol. 25, 718-720
13 Singh,A. et al. (2015) Protein recovery from inclusion bodies of Escherichia coli 
using mild solubilization process. Microb. Cell Fact. 14, 41
14 Speed,M.A. et al. (1996) Specific aggregation of partially folded polypeptide chains: 
the molecular basis of inclusion body composition. Nat. Biotechnol. 14, 1283-1287
15 Morell,M. et al. (2008) Inclusion bodies: specificity in their aggregation process and 
amyloid-like structure. Biochim. Biophys. Acta 1783, 1815-1825
16 Pesarrodona,M. et al. (2014) Intracellular targeting of CD44 cells with self-
assembling, protein only nanoparticles. Int. J. Pharm. 473, 286-295
17 Peternel,S. et al. (2008) Engineering inclusion bodies for non denaturing extraction 
of functional proteins. Microb. Cell Fact. 7, 34
18 Bradford,M.M. (1976) A rapid and sensitive method for the quantitation of microgram
quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 
248-254
19 Eswar,N. et al. (2006) Comparative protein structure modeling using Modeller. Curr. 
Protoc. Bioinformatics Chapter 5, Unit
20 Wizemann,H. et al. (2003) Distinct requirements for heparin and alpha-dystroglycan 
binding revealed by structure-based mutagenesis of the laminin alpha2 LG4-LG5 
domain pair. J. Mol. Biol. 332, 635-642
32
21 Harrison,D. et al. (2007) Crystal structure and cell surface anchorage sites of 
laminin alpha1LG4-5. J. Biol. Chem. 282, 11573-11581
22 Ramakrishnan,V. et al. (1993) Crystal structure of globular domain of histone H5 
and its implications for nucleosome binding. Nature 362, 219-223
23 Barondeau,D.P. et al. (2003) Mechanism and energetics of green fluorescent 
protein chromophore synthesis revealed by trapped intermediate structures. Proc. Natl.
Acad. Sci. U. S. A 100, 12111-12116
24 Shen,M.Y. and Sali,A. (2006) Statistical potential for assessment and prediction of 
protein structures. Protein Sci. 15, 2507-2524
25 Fiorucci,S. and Zacharias,M. (2010) Prediction of protein-protein interaction sites 
using electrostatic desolvation profiles. Biophys. J. 98, 1921-1930
26 Richard,J.P. et al. (2003) Cell-penetrating peptides. A reevaluation of the 
mechanism of cellular uptake. J. Biol. Chem. 278, 585-590
27 de Marco,A. and Schroedel,A. (2005) Characterization of the aggregates formed 
during recombinant protein expression in bacteria. BMC. Biochem. 6, 10
28 Peternel,S. and Komel,R. (2010) Isolation of biologically active nanomaterial 
(inclusion bodies) from bacterial cells. Microb. Cell Fact. 9, 66
29 Jevsevar,S. et al. (2005) Production of nonclassical inclusion bodies from which 
correctly folded protein can be extracted. Biotechnol. Prog. 21, 632-639
30 Garcia-Fruitos,E. et al. (2005) Aggregation as bacterial inclusion bodies does not 
imply inactivation of enzymes and fluorescent proteins. Microb. Cell Fact. 4, 27
31 Cano-Garrido,O. et al. (2013) Supramolecular organization of protein-releasing 
functional amyloids solved in bacterial inclusion bodies. Acta Biomater. 9, 6134-6142
32 Mitraki,A. (2010) Protein aggregation from inclusion bodies to amyloid and 
biomaterials. Adv. Protein Chem. Struct. Biol. 79, 89-125
33 Garcia-Fruitos,E. et al. (2011) Biological role of bacterial inclusion bodies: a model 
for amyloid aggregation. FEBS J. 278, 2419-2427
34 Villar-Pique,A. and Ventura,S. (2012) Modeling amyloids in bacteria. Microb. Cell 
Fact. 11, 166
35 Garcia-Fruitos,E. et al. (2012) Bacterial inclusion bodies: making gold from waste. 
Trends Biotechnol 30, 65-70
36 Vazquez,E. et al. (2010) Protein nanodisk assembling and intracellular trafficking 
powered by an arginine-rich (R9) peptide. Nanomedicine. (Lond) 5, 259-268
37 Salvati,A. et al. (2013) Transferrin-functionalized nanoparticles lose their targeting 
capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol. 8, 
137-143
38 Villaverde,A. (2010) Nanotechnology, bionanotechnology and microbial cell 
factories. Microb. Cell Fact. 9, 53
33
39 Mironov,V. et al. (2009) Biofabrication: a 21st century manufacturing paradigm. 
Biofabrication. 1, 022001
40 Vazquez,E. and Villaverde,A. (2013) Microbial biofabrication for nanomedicine: 
biomaterials, nanoparticles and beyond. Nanomedicine (Lond) 8, 1895-1898
41 Park,T.J. et al. (2015) Advances in microbial biosynthesis of metal nanoparticles. 
Appl. Microbiol. Biotechnol.
42 Vijayendra,S.V. and Shamala,T.R. (2014) Film forming microbial biopolymers for 
commercial applications--a review. Crit Rev. Biotechnol. 34, 338-357
43 Chen,G.Q. (2009) A microbial polyhydroxyalkanoates (PHA) based bio- and 
materials industry. Chem. Soc. Rev. 38, 2434-2446
44 Rodriguez-Carmona,E. and Villaverde,A. (2010) Nanostructured bacterial materials 
for innovative medicines. Trends Microbiol. 18, 423-430
45 Chen,R. (2012) Bacterial expression systems for recombinant protein production: E.
coli and beyond. Biotechnol. Adv. 30, 1102-1107
46 Corchero,J.L. et al. (2013) Unconventional microbial systems for the cost-efficient 
production of high-quality protein therapeutics. Biotechnol. Adv. 31, 140-153
47 Ferrer-Miralles,N. and Villaverde,A. (2013) Bacterial cell factories for recombinant 
protein production; expanding the catalogue. Microb. Cell Fact. 12, 113
48 Chen,G.Q. (2012) New challenges and opportunities for industrial biotechnology. 
Microb. Cell Fact. 11, 111
49 Liu,L. et al. (2013) Recent advances in recombinant protein expression by 
Corynebacterium, Brevibacterium, and Streptomyces: from transcription and translation
regulation to secretion pathway selection. Appl. Microbiol. Biotechnol
50 Rueda,F. et al. (2014) Production of functional inclusion bodies in endotoxin-free 
Escherichia coli. Appl. Microbiol. Biotechnol. 98, 9229-9238
51 Mamat,U. et al. (2015) Detoxifying Escherichia coli for endotoxin-free production of 
recombinant proteins. Microb. Cell Fact. 14, 57
52 Kobayashi,N. et al. (2015) Self-Assembling Nano-Architectures Created from a 
Protein Nano-Building Block Using an Intermolecularly Folded Dimeric de Novo 
Protein. J. Am. Chem. Soc. 137, 11285-11293
53 Hernandez-Garcia,A. et al. (2014) Design and self-assembly of simple coat proteins
for artificial viruses. Nat. Nanotechnol. 9, 698-702
54 Doll,T.A. et al. (2015) Optimizing the design of protein nanoparticles as carriers for 
vaccine applications. Nanomedicine. 11, 1705-1713
55 Kaltofen,S. et al. (2015) Computational de novo design of a self-assembling peptide
with predefined structure. J. Mol. Biol. 427, 550-562
56 Sonmez,C. et al. (2015) Design of self-assembling peptide hydrogelators amenable 
to bacterial expression. Biomaterials 37, 62-72
34
57 Lai,Y.T. et al. (2014) Structure of a designed protein cage that self-assembles into a 
highly porous cube. Nat. Chem. 6, 1065-1071
58 Tamamis,P. et al. (2014) Combination of theoretical and experimental approaches 
for the design and study of fibril-forming peptides. Methods Mol. Biol. 1216, 53-70
59 Bayburt,T.H. and Sligar,S.G. (2010) Membrane protein assembly into Nanodiscs. 
FEBS Lett. 584, 1721-1727
60 Bayburt,T.H. et al. (1998) Reconstitution and imaging of a membrane protein in a 
nanometer-size phospholipid bilayer. J. Struct. Biol. 123, 37-44
61 Rueda,F. et al. (2015) Bottom-Up Instructive Quality Control in the Biofabrication of 
Smart Protein Materials. Adv. Mater. 27, 7816-7822
62 Peternel,S. et al. (2008) New properties of inclusion bodies with implications for 
biotechnology. Biotechnol. Appl. Biochem. 49, 239-246
63 Rejman,J. et al. (2004) Size-dependent internalization of particles via the pathways 
of clathrin- and caveolae-mediated endocytosis. Biochem. J. 377, 159-169
64 Shang,L. et al. (2014) Nanoparticle interactions with live cells: Quantitative 
fluorescence microscopy of nanoparticle size effects. Beilstein. J. Nanotechnol. 5, 
2388-2397
65 Shang,L. et al. (2014) Engineered nanoparticles interacting with cells: size matters. 
J. Nanobiotechnology. 12, 5
66 Unzueta,U. et al. (2015) Towards protein-based viral mimetics for cancer therapies. 
Trends Biotechnol. 33, 253-258
67 Alexis,F. et al. (2008) Factors affecting the clearance and biodistribution of 
polymeric nanoparticles. Mol. Pharm. 5, 505-515
68 Hirn,S. et al. (2011) Particle size-dependent and surface charge-dependent 
biodistribution of gold nanoparticles after intravenous administration. Eur. J. Pharm. 
Biopharm. 77, 407-416
69 Nie,S. (2010) Understanding and overcoming major barriers in cancer 
nanomedicine. Nanomedicine. (Lond) 5, 523-528
70 Garnett,M.C. and Kallinteri,P. (2006) Nanomedicines and nanotoxicology: some 
physiological principles. Occup. Med. (Lond) 56, 307-311
71 Cespedes,M.V. et al. (2014) In Vivo Architectonic Stability of Fully de Novo 
Designed Protein-Only Nanoparticles. ACS Nano. 8, 4166-4176
72 Yang,F. et al. (1996) The molecular structure of green fluorescent protein. Nat. 
Biotechnol 14, 1246-1251
73  (2015) The Fluorophore of Green Fluorescent Protein (GFP). 
http://dwb.unl.edu/Teacher/NSF/C08/C08Links/pps99.cryst.bbk.ac.uk/projects/gmocz/gf
p.htm
35
